BioXcel Therapeutics (BTAI) Return on Assets (2018 - 2026)

BioXcel Therapeutics' Return on Assets history runs 9 years deep, the most recent figure standing at 0.02% for Q1 2026.

• On a quarterly basis, Return on Assets changed 0.0% year-over-year to 0.02% in Q1 2026; TTM through Mar 2026 was 0.02%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.02%, up 3.0% from the prior year.
• Return on Assets retreated to 0.02% in Q1 2026 per BTAI's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Assets topped out at 0.01% in Q3 2022 and bottomed at 0.03% in Q3 2023.
• The 5-year median for Return on Assets is 0.02% (2024), against an average of 0.02%.
• Across the five-year window, Return on Assets decreased 2 bps in 2023 and climbed 2 bps in 2024, its largest moves.
• Year by year, Return on Assets stood at 0.02% in 2022, then plunged by 57 bps to 0.03% in 2023, then surged by 34 bps to 0.02% in 2024, then rose by 12 bps to 0.01% in 2025, then dropped by 14 bps to 0.02% in 2026.
• Per Business Quant, the three latest BTAI Return on Assets figures stand at 0.02% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025).